Kristiansen Glen, Yu Yongwei, Schlüns Karsten, Sers Christine, Dietel Manfred, Petersen Iver
Institute of Pathology, Charité University Hospital, 10117 Berlin, Germany.
Anal Cell Pathol. 2003;25(2):77-81. doi: 10.1155/2003/574829.
Expression of MCAM is observed in a variety of human malignancies. We aimed to determine the rate of MCAM expression in our non-small cell lung cancer (NSCLC) collection and to clarify its correlation with clinicopathological parameters and patient survival. 85 NSCLC were analysed immunohistochemically using a monoclonal MCAM antibody (clone N1238) on an NSCLC tissue micro array. The staining was semiquantitatively scored. We found MCAM expression in 51% of NSCLC, preferentially squamous cell carcinomas (p=0.004). No other correlations to tumour size, grade, or stage were found. Univariate survival analysis showed no significant differences of MCAM positive and negative tumours. In adenocarcinomas however, MCAM positivity was significantly associated with shorter patient survival (p=0.016). We conclude, that MCAM is expressed in a high proportion of NSCLC and might be predictive of shortened patient survival in adenocarcinomas of the lung. Colour figure can be viewed on http://www.esacp.org/acp/2003/25-2/kristiansen.htm
在多种人类恶性肿瘤中均观察到MCAM的表达。我们旨在确定MCAM在我们收集的非小细胞肺癌（NSCLC）中的表达率，并阐明其与临床病理参数及患者生存率的相关性。使用单克隆MCAM抗体（克隆N1238）对85例NSCLC组织芯片进行免疫组织化学分析。对染色进行半定量评分。我们发现51%的NSCLC中存在MCAM表达，在鳞状细胞癌中表达更为常见（p=0.004）。未发现与肿瘤大小、分级或分期有其他相关性。单因素生存分析显示MCAM阳性和阴性肿瘤之间无显著差异。然而，在腺癌中，MCAM阳性与患者生存期较短显著相关（p=0.016）。我们得出结论，MCAM在高比例的NSCLC中表达，并且可能预示着肺腺癌患者生存期缩短。彩色图可在http://www.esacp.org/acp/2003/25-2/kristiansen.htm查看
